Cell and Gene Therapy Manufacturing Services Market Revenue to Reach USD 33.9 Billion by 2033 | Fueled by Transformative Therapies and Expanding Pharmaceutical Demand - Exclusive Report by Transparency Market Research, Inc.

Cell and gene therapy manufacturing services involve introducing cells or genes into patients to treat a wide range of diseases, including various cancers, cardiovascular conditions, and genetic disorders. These therapies, sourced from either the patient or a donor, are cultured, purified, and packaged before being administered via injection or infusion.

In 2022, the global industry was valued at US$ 5.8 billion and is projected to surge to US$ 33.9 billion by 2033, growing at a robust CAGR of 17.4% during the forecast period.

Discover essential conclusions and data from our Report in this sample -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85421

Over the past few years, demand for these services has risen due to their significant health benefits-most notably in treating blood cancers, lymphomas, leukemia, and solid tumors. The U.S. Food and Drug Administration (FDA) has approved breakthrough therapies such as CAR T-cell treatment, paving the way for rapid adoption and innovation in the field and further accelerating market growth

Analysts' Viewpoint

Industry experts note that the cell and gene therapy manufacturing services market is undergoing transformative growth. Historical data from 2017 to 2022 indicates a CAGR of approximately 13.9%, setting a strong foundation for the projected 17.4% CAGR from 2023 to 2033. With an absolute dollar opportunity of US$ 27.1 billion, the market is poised for substantial expansion driven by continuous technological innovations and increasing investment from both public and private sectors. Enhanced manufacturing efficiencies through single-use technologies and improved cell culture techniques are further bolstering market dynamics.

Market Drivers

Health Benefits and Rising Demand for Advanced Therapies

Treatment Efficacy: Cell and gene therapies have shown significant promise in treating life-threatening conditions such as blood cancers, lymphomas, leukemia, and solid tumors.

Breakthrough Approvals: Landmark approvals, including the first CAR T cell therapy in 2017, have reinforced the clinical benefits and accelerated market adoption.

Technological Advancements and Manufacturing Innovations

Innovative Technologies: Advancements in single-use technologies and cell culture techniques are enhancing manufacturing efficiency, consistency, and cost-effectiveness.

Process Improvements: The ability to scale up production while maintaining high product quality is critical for meeting growing demand.

Expanding Pharmaceutical and Biotechnology Investments

Increased Funding: Rising investments in R&D and manufacturing capabilities are propelling the market, with significant growth witnessed in the United States, United Kingdom, France, China, and Japan.

Government Support: Supportive regulatory frameworks and government initiatives worldwide are further accelerating market expansion.

Access our report for a comprehensive look at key insights -

https://www.transparencymarketresearch.com/cell-and-gene-therapy-manufacturing-services-market.html

Market Segmentation

By Type

Cell Therapy:

Allogeneic: Utilizing donor cells to treat patients.

Autologous: Using the patient's own cells, tailored for personalized treatment.

Gene Therapy:

Viral Vector: Employing viral delivery systems to introduce genetic material.

Non-Viral Vector: Alternative delivery methods offering improved safety profiles.

By Indication

Oncology Diseases, Cardiovascular Diseases, Orthopedic Diseases, Ophthalmology Diseases, Central Nervous System Disorders, Infectious Diseases, Other Indications

By Application

Clinical Manufacturing, Commercial Manufacturing

By End-user

Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others

By Region

North America, Latin America, Europe, Asia Pacific, Middle East & Africa

Regional Outlook

North America
North America is a prominent market, valued at US$ 2.3 billion in 2022, and is expected to grow to US$ 13.9 billion by 2033. High incidence rates of cancer and cardiovascular diseases, coupled with robust technological infrastructure, are driving demand for cell and gene therapy manufacturing services in this region.

United States
The U.S. market is set to reach US$ 12 billion by 2033, growing at a CAGR of 17.2% from 2023 to 2033. With ischemic heart disease, stroke, and various cancers contributing to high demand, ongoing innovations and regulatory support are propelling market growth.

Europe
Countries like the United Kingdom and France are witnessing significant investments in cell and gene therapy. The UK market is projected to be worth US$ 1.4 billion by 2033, while France is expected to reach US$ 2.7 billion by the same period, driven by rising cancer cases and government backing.

Asia Pacific
Rapid expansion in healthcare infrastructure and increased investments in biotechnology are fueling growth in China and Japan. China's market is anticipated to grow by US$ 1.5 billion in absolute terms by 2033, whereas Japan's market is expected to reach US$ 1.2 billion.

Competitive Landscape

The global cell and gene therapy manufacturing services market is highly competitive and fragmented, with several key players driving innovation and market share. Prominent companies include:

Lonza

Catalent, Inc.

Thermo Fisher Scientific, Inc.

Charles River Laboratories

WuXi AppTec

Merch KGaA

Takara Bio Inc.

Oxford Biomedica

Novartis

Genezen

Discovery Life Sciences

Recent strategic developments include Catalent's acquisition of Metrics Contract Services for US$ 475 million in August 2022, Lonza's acquisition of Exosomics' service unit in November 2021, and Charles River Laboratories' acquisition of Cognate BioServices in February 2021. These moves underscore the ongoing efforts to enhance manufacturing capabilities and meet the growing market demand.

Future Outlook

The cell and gene therapy manufacturing services market is expected to maintain its robust growth trajectory through 2033, propelled by:

Ongoing Technological Innovations: Continuous advancements in manufacturing processes and single-use technologies will enhance production efficiency and product quality.

Expanding Therapeutic Applications: Increasing adoption of cell and gene therapies across various indications, including oncology, cardiovascular, and infectious diseases, will drive market expansion.

Global Investment and Collaboration: Strategic investments and collaborations among industry stakeholders will foster further innovation and market penetration, particularly in high-growth regions.

Buy this Premium Research Report to access comprehensive analysis -

https://www.transparencymarketresearch.com/checkout.php?rep_id=85421<ype=S

FAQs

Q1: What are cell and gene therapy manufacturing services?
A: These services involve the production of therapies that introduce cells or genetic material into patients to treat diseases such as cancer, cardiovascular disorders, and genetic conditions.

Q2: What factors are driving the growth of this market?
A: Key drivers include the proven clinical benefits in treating various diseases, technological advancements in manufacturing, and increased investments from pharmaceutical and biotechnology companies.

Q3: Which segment is expected to generate the highest revenue?
A: Cell therapy is projected to be the highest revenue-generating segment, with an anticipated CAGR of over 17.1% from 2023 to 2033.

Q4: How is the market performing regionally?
A: North America leads the market, with significant growth observed in the United States. Europe and Asia Pacific are also experiencing robust expansion due to increasing disease prevalence and enhanced healthcare infrastructure.

Q5: Who are the major players in this market?
A: Key players include Lonza, Catalent, Inc., Thermo Fisher Scientific, Inc., Charles River Laboratories, and WuXi AppTec, among others.

This explosive growth is driven by the transformative potential of cell and gene therapies in treating critical diseases, coupled with rapid technological advancements and strong industry investments. As pharmaceutical and biotechnology companies continue to innovate and scale up manufacturing processes, the market is set to revolutionize patient care and deliver improved clinical outcomes across the globe.

Explore Latest Research Reports by Transparency Market Research:

Heart Pumps Market - https://www.transparencymarketresearch.com/heart-pump-devices-market.html

Ingestible Sensors Market - https://www.transparencymarketresearch.com/ingestible-sensors-market.html

Ureteral Stents Market - https://www.transparencymarketresearch.com/ureteral-stents-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube

This release was published on openPR.